Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- 3-D holographic microscopy powered by deep-learning deciphers cancer immunotherapyon February 24, 2021 at 7:35 am
Live tracking and analyzing of the dynamics of chimeric antigen receptor (CAR) T-cells targeting cancer cells can open new avenues for the development of cancer immunotherapy. However, imaging via ...
- An mRNA nanovaccine for cancer immunotherapyon February 24, 2021 at 6:11 am
Researchers have developed a graphene oxide hydrogel that, when injected into mice with melanoma, slowly released RNA nanovaccines that shrank tumors and kept them from metastasizing.
- Cancer immunotherapy market is expected to grow CAGR of around 10.6% during the forecast period 2019 to 2026on February 24, 2021 at 3:55 am
The global cancer immunotherapy market is expected to grow at a noteworthy CAGR of around 10.6% during the forecast period 2019 to 2026 The Cancer Immunotherapy Market size is poised to hit around US$ ...
- Understanding the impact of immune-mediated selection on lung cancer evolutionon February 23, 2021 at 5:26 pm
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. Rachel Rosenthal & Charles Swanton. Cancer Research UK Lung Cancer Centr ...
- The unveiling of a novel mechanism of resistance to immunotherapy targeting HER2on February 23, 2021 at 10:08 am
Immunotherapy continues to show exciting promise in more effectively combating several tumor types. Many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly ...
- Extensive Demand for T-Cell Adoptive Immunotherapy Rising with Growing Prevalence of Canceron February 23, 2021 at 9:36 am
In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue to do so for several years to ...
- Regeneron wins FDA OK in lung cancer for immunotherapy rival to Merck's Keytrudaon February 22, 2021 at 3:39 pm
The approval of Libtayo in first-line lung cancer will pit Regeneron's drug, developed in partnership with Sanofi, against Merck's top-selling immunotherapy Keytruda.
- FDA Grants Fast Track Designation to GEN-1 Immunotherapy for Treatment of Advanced Ovarian Canceron February 22, 2021 at 1:02 pm
Celsion Corporation announced that fast track designation was granted to their immunotherapy, GEN-1, to treat patients with advanced stage III or IV ovarian cancer.
- Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapyon February 19, 2021 at 8:13 pm
Despite great success in cancer immunotherapy, immune checkpoint-targeting drugs are not the most popular weapon in the armory of cancer therapy. Accumulating evidence suggests that the tumor immune ...
- An mRNA vaccine for cancer immunotherapyon February 17, 2021 at 2:02 pm
Messenger RNA (mRNA) vaccines to prevent COVID-19 have made headlines around the world recently, but scientists have also been working on mRNA vaccines to treat ...
via Bing News